George Poste, Michael Dunn, John Mendlein, William Hahne, Henri Lichenstein, Donna Morgan Murray, Richard Shimkets, Steven Henck, Elizabeth Whayland, Jeffry Brown | GenomeWeb

Orchid Biosciences Chairman George Poste was named director of the Arizona Biodesign Institute, Arizona State University’s new biodesign and biotechnology enterprise. Poste is also CEO of Health Technology Networks, a consulting group based in Scottsdale, Ariz. For six years ending in 1999, he was president for R&D and CSO and CTO at SmithKline Beecham.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: flu susceptibility and Y chromosome variation in mice, deletion tied to epilepsy in dog breed, and more.

Sequencing is enabling the roots of some rare diseases to be determined, the Financial Times reports.

Proove Biosciences had allegedly been paying doctors to perform its opioid risk and other genetic tests, Stat News reports.

A floated budget plan could see non-military discretionary spending in the US — which includes science agency funding — fall, the New York Times reports.